Hybrid tandem and ovoids brachytherapy in locally advanced cervical cancer: Impact of dose and tumor volume metrics on outcomes

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To report the impact of dose and tumor volume metrics at brachytherapy on outcomes for locally advanced cervical cancer treated with tandem and ovoids intracavitary/interstitial brachytherapy. Material and methods: FIGO stage IB1-IIIB locally advanced cervical cancer treated with intracavitary/interstitial brachytherapy via a tandem and ovoids hybrid applicator were analyzed. Median high-risk clinical target volume (HR-CTV), rate of tumor volume reduction, EQD2D90, organ at risk doses, and outcomes were recorded. Univariable and multivariable Cox regression was applied for survival analysis, and logistic regression was used for toxicity analysis. Results: Seventy-one patients were identified. Median follow-up was 24.9 months, with a 2-year local control of 83.6%, loco-regional control of 72.0%, and overall survival of 88.6%. Median HR-CTV D90was 87.4 Gy (IQR = 85.7-90.2). Median HR-CTV D90> 90 Gy10 showed a trend toward improved local control (LC) (p = 0.19). Median HR-CTV was 37.9 cm3, and median V100 was 86.5%. A median HR-CTV of ≥ 40 cm3demonstrated worse loco-regional control (LRC) (p = 0.018) and progression-free survival (p = 0.021). Two-year LC and LRC for stage IIB patients with a median HR-CTV < 40 cm3were significantly improved as compared to ≥ 40 cm3at 100% and 71.8%, respectively (p = 0.019) and 100% and 56.5%, respectively (p = 0.001). However, this trend was not statistically significant for stage IIIB patients. Higher percent per day reduction in HR-CTV during brachytherapy showed improved LRC (p = 0.045). Four percent of patients experienced acute grade 3 genitourinary toxicity, 1% late grade 3 genitourinary and 1% late grade 3 gastrointestinal toxicity. Conclusions: Tandem and ovoids intracavitary/interstitial brachytherapy provides satisfactory outcomes with modest toxicity. Higher HR-CTV D90coverage demonstrated a trend toward improved tumor control. Tumor volume based on median HR-CTV ≥ 40 cm3at brachytherapy was prognostic for poor outcomes, even within initial FIGO stage groups warranting caution.

Original languageEnglish (US)
Pages (from-to)158-166
Number of pages9
JournalJournal of Contemporary Brachytherapy
Volume13
Issue number2
DOIs
StatePublished - 2021

Keywords

  • Brachytherapy
  • Cervical cancer
  • Hybrid device
  • Tandem and ovoids

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Hybrid tandem and ovoids brachytherapy in locally advanced cervical cancer: Impact of dose and tumor volume metrics on outcomes'. Together they form a unique fingerprint.

Cite this